Build Your Comparison

Side-by-side financial analysis
BLLN logo
BLLN
EXAS logo
EXAS
KO logo
KO
Try popular comparisons:

Stock Comparison

BLLN vs EXAS vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BLLN
BillionToOne, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$4.65B
5Y Perf.-1.5%
EXAS
Exact Sciences Corporation

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$20.02B
5Y Perf.+20.7%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+82.5%

BLLN vs EXAS vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BLLN logoBLLN
EXAS logoEXAS
KO logoKO
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchBeverages - Non-Alcoholic
Market Cap$4.65B$20.02B$355.61B
Revenue (TTM)$355M$3.25B$49.28B
Net Income (TTM)$25M$-208M$13.70B
Gross Margin70.4%69.7%61.7%
Operating Margin10.2%-6.4%29.3%
Forward P/E102.7x582.8x25.3x
Total Debt$109M$2.52B$45.49B
Cash & Equiv.$496M$956M$10.27B

BLLN vs EXAS vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BLLN
EXAS
KO
StockJun 20Mar 26Return
Exact Sciences Corp… (EXAS)100120.7+20.7%
The Coca-Cola Compa… (KO)100182.5+82.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: BLLN vs EXAS vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. BillionToOne, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
BLLN
BillionToOne, Inc.
The Growth Play

BLLN is the clearest fit if your priority is growth exposure and sleep-well-at-night.

  • Rev growth 100.0%, EPS growth 106.8%
  • Lower volatility, beta 1.91, Low D/E 22.7%, current ratio 11.69x
  • Beta 1.91, current ratio 11.69x
Best for: growth exposure and sleep-well-at-night
EXAS
Exact Sciences Corporation
The Momentum Pick

EXAS is the clearest fit if your priority is momentum.

  • +94.2% vs BLLN's -7.2%
Best for: momentum
KO
The Coca-Cola Company
The Long-Run Compounder

KO carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • 121.1% 10Y total return vs EXAS's 13.9%
  • Lower P/E (25.3x vs 102.7x)
  • 27.8% margin vs EXAS's -6.4%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBLLN logoBLLN100.0% revenue growth vs KO's 1.9%
ValueKO logoKOLower P/E (25.3x vs 102.7x)
Quality / MarginsKO logoKO27.8% margin vs EXAS's -6.4%
Stability / SafetyBLLN logoBLLNLower D/E ratio (22.7% vs 132.7%)
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)EXAS logoEXAS+94.2% vs BLLN's -7.2%
Efficiency (ROA)KO logoKO13.1% ROA vs EXAS's -3.5%, ROIC 15.8% vs -3.6%

BLLN vs EXAS vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BLLNBillionToOne, Inc.

Segment breakdown not available.

EXASExact Sciences Corporation
FY 2025
Screening
77.9%$2.5B
Precision Oncology
22.1%$717M
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

BLLN vs EXAS vs KO — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLEXASLAGGINGBLLN

Income & Cash Flow (Last 12 Months)

Evenly matched — BLLN and KO each lead in 3 of 6 comparable metrics.

KO is the larger business by revenue, generating $49.3B annually — 139.0x BLLN's $355M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to EXAS's -6.4%. On growth, BLLN holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBLLN logoBLLNBillionToOne, Inc.EXAS logoEXASExact Sciences Co…KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$355M$3.2B$49.3B
EBITDAEarnings before interest/tax$44M-$41M$15.5B
Net IncomeAfter-tax profit$25M-$208M$13.7B
Free Cash FlowCash after capex$28M$357M$12.6B
Gross MarginGross profit ÷ Revenue+70.4%+69.7%+61.7%
Operating MarginEBIT ÷ Revenue+10.2%-6.4%+29.3%
Net MarginNet income ÷ Revenue+7.1%-6.4%+27.8%
FCF MarginFCF ÷ Revenue+7.9%+11.0%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+83.8%+23.1%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+4.8%+90.4%+18.2%
Evenly matched — BLLN and KO each lead in 3 of 6 comparable metrics.

Valuation Metrics

EXAS leads this category, winning 4 of 6 comparable metrics.

At 27.2x trailing earnings, KO trades at a 98% valuation discount to BLLN's 1587.4x P/E. On an enterprise value basis, KO's 26.4x EV/EBITDA is more attractive than BLLN's 266.1x.

MetricBLLN logoBLLNBillionToOne, Inc.EXAS logoEXASExact Sciences Co…KO logoKOThe Coca-Cola Com…
Market CapShares × price$4.7B$20.0B$355.6B
Enterprise ValueMkt cap + debt − cash$4.3B$21.6B$390.8B
Trailing P/EPrice ÷ TTM EPS1587.44x-95.37x27.18x
Forward P/EPrice ÷ next-FY EPS est.102.72x582.83x25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple266.12x26.39x
Price / SalesMarket cap ÷ Revenue15.24x6.16x7.42x
Price / BookPrice ÷ Book value/share9.65x8.24x10.40x
Price / FCFMarket cap ÷ FCF295.98x56.10x67.15x
EXAS leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — BLLN and KO each lead in 4 of 8 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-9 for EXAS. BLLN carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x.

MetricBLLN logoBLLNBillionToOne, Inc.EXAS logoEXASExact Sciences Co…KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity+7.6%-8.7%+41.1%
ROA (TTM)Return on assets+5.1%-3.5%+13.1%
ROICReturn on invested capital+13.5%-3.6%+15.8%
ROCEReturn on capital employed+3.7%-4.0%+17.3%
Piotroski ScoreFundamental quality 0–9777
Debt / EquityFinancial leverage0.23x1.05x1.33x
Net DebtTotal debt minus cash-$387M$1.6B$35.2B
Cash & Equiv.Liquid assets$496M$956M$10.3B
Total DebtShort + long-term debt$109M$2.5B$45.5B
Interest CoverageEBIT ÷ Interest expense516.43x-5.47x10.70x
Evenly matched — BLLN and KO each lead in 4 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

KO leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $8,392 for EXAS. Over the past 12 months, EXAS leads with a +94.2% total return vs BLLN's -7.2%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs BLLN's -2.5% — a key indicator of consistent wealth creation.

MetricBLLN logoBLLNBillionToOne, Inc.EXAS logoEXASExact Sciences Co…KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date+13.2%+3.1%+20.3%
1-Year ReturnPast 12 months-7.2%+94.2%+17.2%
3-Year ReturnCumulative with dividends-7.2%+15.2%+47.0%
5-Year ReturnCumulative with dividends-7.2%-16.1%+65.6%
10-Year ReturnCumulative with dividends-7.2%+1390.2%+121.1%
CAGR (3Y)Annualised 3-year return-2.5%+4.8%+13.7%
KO leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — EXAS and KO each lead in 1 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than BLLN's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs BLLN's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBLLN logoBLLNBillionToOne, Inc.EXAS logoEXASExact Sciences Co…KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5001.91x-0.05x-0.20x
52-Week HighHighest price in past year$138.70$104.98$84.04
52-Week LowLowest price in past year$61.96$38.81$65.35
% of 52W HighCurrent price vs 52-week peak+72.9%+99.9%+98.3%
RSI (14)Momentum oscillator 0–10056.576.460.6
Avg Volume (50D)Average daily shares traded642K21.6M12.7M
Evenly matched — EXAS and KO each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: BLLN as "Buy", EXAS as "Buy", KO as "Buy". Consensus price targets imply 23.6% upside for BLLN (target: $125) vs 0.1% for EXAS (target: $105). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricBLLN logoBLLNBillionToOne, Inc.EXAS logoEXASExact Sciences Co…KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$125.00$105.00$86.13
# AnalystsCovering analysts44148
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises56
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.1%+0.2%
Insufficient data to determine a leader in this category.
Key Takeaway

EXAS leads in 1 of 6 categories (Valuation Metrics). KO leads in 1 (Total Returns). 3 tied.

Best OverallExact Sciences Corporation (EXAS)Leads 1 of 6 categories
Loading custom metrics...

BLLN vs EXAS vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BLLN or EXAS or KO a better buy right now?

For growth investors, BillionToOne, Inc.

(BLLN) is the stronger pick with 100. 0% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate BillionToOne, Inc. (BLLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BLLN or EXAS or KO?

On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.

2x versus BillionToOne, Inc. at 1587. 4x. On forward P/E, The Coca-Cola Company is actually cheaper at 25. 3x.

03

Which is the better long-term investment — BLLN or EXAS or KO?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -16. 1% for Exact Sciences Corporation (EXAS). Over 10 years, the gap is even starker: EXAS returned +1390% versus BLLN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BLLN or EXAS or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus BillionToOne, Inc. 's 1. 91β — meaning BLLN is approximately -1053% more volatile than KO relative to the S&P 500. On balance sheet safety, BillionToOne, Inc. (BLLN) carries a lower debt/equity ratio of 23% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — BLLN or EXAS or KO?

By revenue growth (latest reported year), BillionToOne, Inc.

(BLLN) is pulling ahead at 100. 0% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: BillionToOne, Inc. grew EPS 106. 8% year-over-year, compared to 23. 6% for The Coca-Cola Company. Over a 3-year CAGR, EXAS leads at 15. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BLLN or EXAS or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -6. 4% for Exact Sciences Corporation — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -6. 4% for EXAS. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BLLN or EXAS or KO more undervalued right now?

On forward earnings alone, The Coca-Cola Company (KO) trades at 25.

3x forward P/E versus 582. 8x for Exact Sciences Corporation — 557. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLLN: 23. 6% to $125. 00.

08

Which pays a better dividend — BLLN or EXAS or KO?

In this comparison, KO (2.

5% yield) pays a dividend. BLLN, EXAS do not pay a meaningful dividend and should not be held primarily for income.

09

Is BLLN or EXAS or KO better for a retirement portfolio?

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

05), +1390% 10Y return). BillionToOne, Inc. (BLLN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1390%, BLLN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BLLN and EXAS and KO?

These companies operate in different sectors (BLLN (Healthcare) and EXAS (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BLLN is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; KO is a large-cap quality compounder stock. KO pays a dividend while BLLN, EXAS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.